Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment

Application of tumor genome sequencing has identified numerous loss-of-function alterations in cancer cells. While these alterations are difficult to target using direct interventions, they may be attacked with the help of the synthetic lethality (SL) approach. In this approach, inhibition of one ge...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Paul, James M., Toosi, Behzad, Vizeacoumar, Frederick S., Bhanumathy, Kalpana Kalyanasundaram, Li, Yue, Gerger, Courtney, Zawily, Amr El, Freywald, Tanya, Anderson, Deborah H., Mousseau, Darrell, Kanthan, Rani, Zhang, Zhaolei, Vizeacoumar, Franco J., Freywald, Andrew
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226566/
https://ncbi.nlm.nih.gov/pubmed/27418135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10569
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars